MONTREAL, QUEBEC--(Marketwire - January 22, 2008) - Ambrilia Biopharma Inc. (TSX: AMB) reported preliminary Phase III results today for its proprietary prolonged-release formulation of Octreotide (“C2L”) in acromegaly patients. The primary objective of this study comparing C2L to Sandostatin®LAR was met with both C2L and Sandostatin® LAR, inducing a highly statistically significant decrease of Insulin-like Growth Factor 1 (“IGF-1") (p less than0.005 for both arms) and Growth Hormone (“GH”) (p less than0.0001 for both arms) plasma levels. It was not possible to demonstrate non-inferiority, nor inferiority, of C2L over Sandostatin®LAR. The Company believes that it would have been difficult to reach this endpoint due to the small patient population and large initial differences in both IGF-1 and GH values. There were no dropouts during the study. No differences were observed between the two products in adverse events, which were mild and transient.
